Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Related Articles by Review for PubMed (Select 22370325)

1.

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R.

J Clin Oncol. 2012 Jun 1;30(16):1919-25. doi: 10.1200/JCO.2011.38.1095. Epub 2012 Feb 27.

4.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
5.

Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.

Croxtall JD, McKeage K.

Drugs. 2011 Feb 12;71(3):363-80. doi: 10.2165/11204810-000000000-00000. Review.

PMID:
21319872
6.

Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).

Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW.

Curr Med Res Opin. 2012 Aug;28(8):1263-79. doi: 10.1185/03007995.2012.707643. Epub 2012 Jul 16. Review.

PMID:
22738819
7.

Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

Buzdar A.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

PMID:
12756078
8.

Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.

Jones SE, Pippen J.

Clin Breast Cancer. 2005 Apr;6 Suppl 1:S9-14. Review.

PMID:
15865850
9.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
10.

Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.

Wiseman LR, Adkins JC.

Drugs Aging. 1998 Oct;13(4):321-32. Review.

PMID:
9805213
11.
12.

Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.

Jones SE.

Semin Oncol. 2003 Oct;30(5 Suppl 16):14-20. Review.

PMID:
14613022
14.

Fulvestrant in postmenopausal women with advanced breast cancer.

Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, Rosario LA, Williams GM, Yang P, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2003 Oct 1;9(12):4309-17. Review.

15.

Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.

Tobias JS.

Int J Biochem Cell Biol. 2004 Nov;36(11):2112-9. Review.

PMID:
15313457
16.

A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.

Howell A, Robertson JF, Vergote I.

Breast Cancer Res Treat. 2003 Dec;82(3):215-22. Review.

PMID:
14703069
17.

Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

Aapro MS, Forbes JF.

Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review.

PMID:
14535530
18.

Preliminary data from ongoing adjuvant aromatase inhibitor trials.

Goss PE.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4397s-4401s; discussion 4411s-4412s. Review.

PMID:
11916231
19.

Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.

Glück S.

Am J Clin Oncol. 2010 Jun;33(3):314-9. doi: 10.1097/COC.0b013e31819fdf9b. Review.

PMID:
19730353
20.

Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.

Gradishar W.

Expert Rev Anticancer Ther. 2005 Jun;5(3):445-53. Review.

PMID:
16001952
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk